Patents by Inventor Martha E. Gadd

Martha E. Gadd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TOPICAL OCULAR ANALGESIC AGENTS
    Publication number: 20160089375
    Abstract: The topical ophthalmic use of certain 2,4-diamino-substituted 1,3-triazines for preventing or alleviating ocular pain in patients is disclosed. Topical ocular pharmaceutical composition are also disclosed.
    Type: Application
    Filed: October 9, 2015
    Publication date: March 31, 2016
    Inventors: Martha E. Gadd, Peter G. Klimko, Karen C. David, Kenneth C. Appell, Mark R. Hellberg
  • Topical ocular analgesic agents
    Patent number: 9187468
    Abstract: The topical ophthalmic use of certain 2,4-diamino-substituted 1,3-triazines for preventing or alleviating ocular pain in patients is disclosed. Topical ocular pharmaceutical composition are also disclosed.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: November 17, 2015
    Assignee: NOVARTIS AG
    Inventors: Martha E. Gadd, Peter G. Klimko, Karen C. David, Kenneth C. Appell, Mark R. Hellberg
  • TOPICAL OCULAR ANALGESIC AGENTS
    Publication number: 20140228338
    Abstract: The topical ophthalmic use of certain 2,4-diamino-substituted 1,3-triazines for preventing or alleviating ocular pain in patients is disclosed. Topcial ocular pharmaceutical composition are also disclosed.
    Type: Application
    Filed: February 13, 2014
    Publication date: August 14, 2014
    Applicant: Novartis AG
    Inventors: Martha E. Gadd, Peter G. Klimko, Karen C. David, Kenneth C. Appell, Mark R. Hellberg
  • Use of FAAH antagonists for treating dry eye and ocular pain
    Patent number: 8207226
    Abstract: Methods of treating symptoms of dry eye by administering a fatty acid amide or inhibitors of fatty acid amide hydrolase (FAAH) are disclosed. Methods of preventing or alleviating ocular pain by administering a fatty acid amide or FAAH inhibitors are also disclosed.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: June 26, 2012
    Assignee: Alcon Research, Ltd.
    Inventors: Martha E. Gadd, Karen C. David
  • MODULATION OF POLYSIALYLATED NEURAL ADHESION MOLECULES (PSA-NCAM) AS A REGULATOR OF OCULAR DISEASE
    Publication number: 20080132451
    Abstract: A method of treating dry eye or dry eye symptom includes topically administering a formulation to the eye. The formulation includes an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of PSA-NCAM. The administered formulation treats dry eye or dry eye symptoms. A method of stimulating the expression of PSA-NCAM in neural beds of an eye includes topically administering a formulation to the eye. The formulation includes an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of PSA-NCAM. The administered formulation may stimulate the expression of PSA-NCAM in the neural beds of the eye. A formulation includes an ophthalmically acceptable carrier and a therapeutically effective amount of a positive modulator of polysialic acid-neural cell adhesion molecule (PSA-NCAM).
    Type: Application
    Filed: November 29, 2007
    Publication date: June 5, 2008
    Applicant: Alcon Manufacturing Ltd.
    Inventors: Martha E. Gadd, Gustav Graff